Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
1.200
0.00 (0.00%)
Feb 21, 2025, 4:00 PM EST - Market closed
Plus Therapeutics Employees
Plus Therapeutics had 20 employees as of December 31, 2023. The number of employees increased by 3 or 17.65% compared to the previous year.
Employees
20
Change (1Y)
3
Growth (1Y)
17.65%
Revenue / Employee
$286,250
Profits / Employee
-$644,250
Market Cap
7.08M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
PSTV News
- 2 days ago - Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer - GlobeNewsWire
- 4 days ago - Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program - GlobeNewsWire
- 2 months ago - Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 2 months ago - Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 2 months ago - Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply - GlobeNewsWire
- 3 months ago - Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference - GlobeNewsWire
- 3 months ago - Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases - GlobeNewsWire
- 3 months ago - Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases - GlobeNewsWire